SCHEMBL365566

SCHEMBL365566

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCI)c3ccccc23)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.78
MAPK12 P53778 10/20 0.78
HCK P08631 9/20 0.78
TNF P01375 5/20 0.78
CIT O14578 1/20 0.74
MUSK O15146 1/20 0.74
MAPK13 O15264 1/20 0.74
MAP3K7 O43318 1/20 0.74
RIPK2 O43353 1/20 0.74
STK10 O94804 1/20 0.74
MAP4K4 O95819 1/20 0.74
CHEK2 O96017 1/20 0.74
ABL1 P00519 1/20 0.74
EGFR P00533 1/20 0.74
RAF1 P04049 1/20 0.74
NTRK1 P04629 1/20 0.74
HSPB1 P04792 1/20 0.74
PRKCB P05771 1/20 0.74
LCK P06239 1/20 0.74
FYN P06241 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6298579 0.92 MAPK14 (0.79) MAPK14MAPK12HCKTNFCIT
SCHEMBL295686 0.88 MAPK14 (1.00) MAPK14MAPK12HCKTNFSRC
SCHEMBL29593358 0.88 MAPK14 (1.00) MAPK14MAPK12HCKTNFSRC
SCHEMBL296321 0.88 MAPK14 (0.72) MAPK14MAPK12HCKTNFCIT
SCHEMBL29594554 0.88 MAPK14 (0.72) MAPK14MAPK12HCKTNFCIT
SCHEMBL6680086 0.87 MAPK14 (0.72) MAPK14MAPK12HCKTNFCIT
SCHEMBL295612 0.87 MAPK14 (0.92) MAPK14MAPK12HCKTNFSRC
SCHEMBL29594379 0.87 MAPK14 (0.92) MAPK14MAPK12HCKTNFSRC
SCHEMBL12444980 0.87 MAPK14 (0.85) MAPK14MAPK12HCKTNFCIT
SCHEMBL29594407 0.86 MAPK14 (0.72) MAPK14MAPK12HCKTNFCIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975285-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-03-10 US disclosed
US-8975285-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-03-10 US disclosed
US-20140114064-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2014-04-24 US disclosed
US-8618140-B2 P38 MAP kinase inhibitors RESPIVERT LTD (GB) 2013-12-31 US disclosed
US-20130012512-A1 P38 MAP kinase inhibitors ITO KAZUHIRO (GB) 2013-01-10 US disclosed
US-20130012512-A1 P38 MAP kinase inhibitors ITO KAZUHIRO (GB) 2013-01-10 US disclosed
US-8293748-B2 p38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2012-10-23 US disclosed
US-8293748-B2 p38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2012-10-23 US disclosed
EP-1147104-B1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMA (US) 2012-03-14 EP disclosed
US-20110212962-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-09-01 US disclosed
US-20110212962-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012512-A1 P38 MAP kinase inhibitors MAPK1, MAPK3, MAPK6 MAPK14 33/4885MAPK12 31/4885HCK 2830/4885
US-20110212962-A1 P38 MAP KINASE INHIBITORS MAPK1, MAPK3, MAPK6 MAPK14 33/4885MAPK12 31/4885HCK 2830/4885
US-20140114064-A1 P38 MAP KINASE INHIBITORS MAPK1, MAPK3, MAPK6 MAPK14 33/4885MAPK12 31/4885HCK 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.